AU2015258100B2 - Heterocyclyl-butanamide derivatives - Google Patents
Heterocyclyl-butanamide derivatives Download PDFInfo
- Publication number
- AU2015258100B2 AU2015258100B2 AU2015258100A AU2015258100A AU2015258100B2 AU 2015258100 B2 AU2015258100 B2 AU 2015258100B2 AU 2015258100 A AU2015258100 A AU 2015258100A AU 2015258100 A AU2015258100 A AU 2015258100A AU 2015258100 B2 AU2015258100 B2 AU 2015258100B2
- Authority
- AU
- Australia
- Prior art keywords
- oxo
- butyl
- methyl
- piperidin
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC(NC1=O)=CN(C=C*C*)C1=CN Chemical compound CC(NC1=O)=CN(C=C*C*)C1=CN 0.000 description 6
- HAQKJTYYFJFWSB-UHFFFAOYSA-N CC(N1)=NC(CCOC2)=C2C1=O Chemical compound CC(N1)=NC(CCOC2)=C2C1=O HAQKJTYYFJFWSB-UHFFFAOYSA-N 0.000 description 2
- ITCQNWXLNZGEHP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(N(C)OC)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(N(C)OC)=O)=O ITCQNWXLNZGEHP-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(O)=O)=O JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- VFLZKCZYEYYAMK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c(cc1C)ccc1OC)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c(cc1C)ccc1OC)=O)=O VFLZKCZYEYYAMK-UHFFFAOYSA-N 0.000 description 1
- YIXOSBXILMNLEC-UHFFFAOYSA-N CC(C)(c(cc1)ccc1C(C(CC1)CCN1C(CCCC(NC1=O)=N[n]2c1ccc2)=O)=O)O Chemical compound CC(C)(c(cc1)ccc1C(C(CC1)CCN1C(CCCC(NC1=O)=N[n]2c1ccc2)=O)=O)O YIXOSBXILMNLEC-UHFFFAOYSA-N 0.000 description 1
- OXIKVZKZCCLUQD-UHFFFAOYSA-N CC(C)C(N=C(CCCC(O)=O)N1)=CC1=C Chemical compound CC(C)C(N=C(CCCC(O)=O)N1)=CC1=C OXIKVZKZCCLUQD-UHFFFAOYSA-N 0.000 description 1
- MNIKKPHWWBUBCL-UHFFFAOYSA-N CC(C)C(N=C(N)N1)=CC1=O Chemical compound CC(C)C(N=C(N)N1)=CC1=O MNIKKPHWWBUBCL-UHFFFAOYSA-N 0.000 description 1
- KSMHFADFTBKKMJ-UHFFFAOYSA-N CC(C)[n]1ncc(C(C(CC2)CCN2C(CCCC(N2)=C[n]3nc(C)cc3C2=O)=O)=O)c1 Chemical compound CC(C)[n]1ncc(C(C(CC2)CCN2C(CCCC(N2)=C[n]3nc(C)cc3C2=O)=O)=O)c1 KSMHFADFTBKKMJ-UHFFFAOYSA-N 0.000 description 1
- QDQAGVUXRXSFDQ-UHFFFAOYSA-N CC(C)[n]1ncc(C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)nc3)c3C2=C)=O)=C)c1 Chemical compound CC(C)[n]1ncc(C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)nc3)c3C2=C)=O)=C)c1 QDQAGVUXRXSFDQ-UHFFFAOYSA-N 0.000 description 1
- APWRLAZEMYLHKZ-UHFFFAOYSA-N CC1=C(C)N=C(N)NC1=O Chemical compound CC1=C(C)N=C(N)NC1=O APWRLAZEMYLHKZ-UHFFFAOYSA-N 0.000 description 1
- QDSSWFSXBZSFQO-UHFFFAOYSA-N CCC(N=C(N)N1)=CC1=O Chemical compound CCC(N=C(N)N1)=CC1=O QDSSWFSXBZSFQO-UHFFFAOYSA-N 0.000 description 1
- UCQJODMMTUAVHP-UHFFFAOYSA-N CC[n]1ncc(C(C(CC2)CCN2C(CCCC(NC2=C)=N[n]3c2ccc3C)=O)=C)c1 Chemical compound CC[n]1ncc(C(C(CC2)CCN2C(CCCC(NC2=C)=N[n]3c2ccc3C)=O)=C)c1 UCQJODMMTUAVHP-UHFFFAOYSA-N 0.000 description 1
- BSCAZSQTZDONDA-UHFFFAOYSA-N COc(c(F)c1)ccc1C(C(CC1)CCN1C(CCCC(NC1=O)=N[n]2c1ccc2)=O)=O Chemical compound COc(c(F)c1)ccc1C(C(CC1)CCN1C(CCCC(NC1=O)=N[n]2c1ccc2)=O)=O BSCAZSQTZDONDA-UHFFFAOYSA-N 0.000 description 1
- VCUOESLZZMKNTE-UHFFFAOYSA-N COc(cc1)ccc1C(C(CC1)CCN1C(CCCC(N1)=NC(CCCC2)=C2C1=O)=O)=O Chemical compound COc(cc1)ccc1C(C(CC1)CCN1C(CCCC(N1)=NC(CCCC2)=C2C1=O)=O)=O VCUOESLZZMKNTE-UHFFFAOYSA-N 0.000 description 1
- MZAHKXMWIOIGHD-UHFFFAOYSA-N C[n]1ncc2c1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1Cl)=O)=O)NC2=O Chemical compound C[n]1ncc2c1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1Cl)=O)=O)NC2=O MZAHKXMWIOIGHD-UHFFFAOYSA-N 0.000 description 1
- XGDHAOYPJGRQIA-UHFFFAOYSA-N Cc([s]cc12)c1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=O)=O)NC2=O Chemical compound Cc([s]cc12)c1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=O)=O)NC2=O XGDHAOYPJGRQIA-UHFFFAOYSA-N 0.000 description 1
- XCKJCVBNKDCEID-UHFFFAOYSA-N Cc(c(C)c1)ccc1C(C(CC1)CCN1C(CCCC(N1)=Nc([n](C)cc2)c2C1=O)=O)=O Chemical compound Cc(c(C)c1)ccc1C(C(CC1)CCN1C(CCCC(N1)=Nc([n](C)cc2)c2C1=O)=O)=O XCKJCVBNKDCEID-UHFFFAOYSA-N 0.000 description 1
- LFKAYRUXVUJZRJ-UHFFFAOYSA-N Cc(cc(cc1)C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)nc3)c3C2=O)=O)=O)c1F Chemical compound Cc(cc(cc1)C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)nc3)c3C2=O)=O)=O)c1F LFKAYRUXVUJZRJ-UHFFFAOYSA-N 0.000 description 1
- CPANXPYCBSUJJE-UHFFFAOYSA-N Cc(cc1)ccc1C(C(CC1)CCN1C(CCCC(N1)=NC(CCOC2)=C2C1=O)=O)=O Chemical compound Cc(cc1)ccc1C(C(CC1)CCN1C(CCCC(N1)=NC(CCOC2)=C2C1=O)=O)=O CPANXPYCBSUJJE-UHFFFAOYSA-N 0.000 description 1
- KMKPBIIMNOEOMP-UHFFFAOYSA-N Cc(cc12)c[n]1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=O)=O)NC2=O Chemical compound Cc(cc12)c[n]1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=O)=O)NC2=O KMKPBIIMNOEOMP-UHFFFAOYSA-N 0.000 description 1
- QWICVSQASLWBDB-UHFFFAOYSA-N Cc1c[s]c2c1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1OC)=C)=O)NC2=O Chemical compound Cc1c[s]c2c1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1OC)=C)=O)NC2=O QWICVSQASLWBDB-UHFFFAOYSA-N 0.000 description 1
- VGXKSGAHZSFPET-UHFFFAOYSA-N Cc1c[s]c2c1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=C)=O)NC2=C Chemical compound Cc1c[s]c2c1N=C(CCCC(N(CC1)CCC1C(c1c[n](C)nc1)=C)=O)NC2=C VGXKSGAHZSFPET-UHFFFAOYSA-N 0.000 description 1
- ANJMISICLSYUGD-UHFFFAOYSA-N Cc1cc(C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)cc3)c3C2=O)=O)=O)ccc1F Chemical compound Cc1cc(C(C(CC2)CCN2C(CCCC(N2)=Nc([n](C)cc3)c3C2=O)=O)=O)ccc1F ANJMISICLSYUGD-UHFFFAOYSA-N 0.000 description 1
- IYDNRLIKQMCUMC-UHFFFAOYSA-N Cc1cc(C(C(CC2)CCN2C(CCCC(NC2=O)=C[n]3c2ccc3)=O)=O)ccc1O Chemical compound Cc1cc(C(C(CC2)CCN2C(CCCC(NC2=O)=C[n]3c2ccc3)=O)=O)ccc1O IYDNRLIKQMCUMC-UHFFFAOYSA-N 0.000 description 1
- WMCDVCYUQWLJHL-UHFFFAOYSA-N Cc1cc(C(C2CCNCC2)=O)ccc1O Chemical compound Cc1cc(C(C2CCNCC2)=O)ccc1O WMCDVCYUQWLJHL-UHFFFAOYSA-N 0.000 description 1
- DKYKPXBMURYMSB-UHFFFAOYSA-N Cc1ccc2[n]1C=C(CCCC(N(CC1)CCC1Oc(cc1)ccc1C#N)=O)NC2=C Chemical compound Cc1ccc2[n]1C=C(CCCC(N(CC1)CCC1Oc(cc1)ccc1C#N)=O)NC2=C DKYKPXBMURYMSB-UHFFFAOYSA-N 0.000 description 1
- QKMGDGKOQFSBGM-UHFFFAOYSA-N Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1OC)=O)=O)NC2=O Chemical compound Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1OC)=O)=O)NC2=O QKMGDGKOQFSBGM-UHFFFAOYSA-N 0.000 description 1
- TUQLEVJPDCCRPL-UHFFFAOYSA-N Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1C(c(cc1C)ccc1OC)=O)=O)NC2=O Chemical compound Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1C(c(cc1C)ccc1OC)=O)=O)NC2=O TUQLEVJPDCCRPL-UHFFFAOYSA-N 0.000 description 1
- IGGZFCKOEQTCIR-UHFFFAOYSA-N Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1Oc(cc1)ccc1C#N)=O)NC2=C Chemical compound Cc1ccc2[n]1N=C(CCCC(N(CC1)CCC1Oc(cc1)ccc1C#N)=O)NC2=C IGGZFCKOEQTCIR-UHFFFAOYSA-N 0.000 description 1
- NXFIJGCUOMGWPC-UHFFFAOYSA-N Cc1cnc2[n]1C=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1O)=O)=O)NC2=O Chemical compound Cc1cnc2[n]1C=C(CCCC(N(CC1)CCC1C(c(cc1)ccc1O)=O)=O)NC2=O NXFIJGCUOMGWPC-UHFFFAOYSA-N 0.000 description 1
- NLMVYUBGWZWUGB-UHFFFAOYSA-N Nc1n[o]c2c1cccc2 Chemical compound Nc1n[o]c2c1cccc2 NLMVYUBGWZWUGB-UHFFFAOYSA-N 0.000 description 1
- WTYSCLHDMXBMKM-UHFFFAOYSA-N Nc1nncc2c1cccc2 Chemical compound Nc1nncc2c1cccc2 WTYSCLHDMXBMKM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001613 | 2014-05-07 | ||
| EP14001613.0 | 2014-05-07 | ||
| PCT/EP2015/000793 WO2015169421A1 (en) | 2014-05-07 | 2015-04-16 | Heterocyclyl-butanamide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015258100A1 AU2015258100A1 (en) | 2016-12-22 |
| AU2015258100B2 true AU2015258100B2 (en) | 2019-05-16 |
Family
ID=50685736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015258100A Ceased AU2015258100B2 (en) | 2014-05-07 | 2015-04-16 | Heterocyclyl-butanamide derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9809598B2 (enExample) |
| EP (1) | EP3140295B1 (enExample) |
| JP (2) | JP6673853B2 (enExample) |
| KR (1) | KR102415436B1 (enExample) |
| CN (1) | CN106458988B (enExample) |
| AR (1) | AR100333A1 (enExample) |
| AU (1) | AU2015258100B2 (enExample) |
| BR (1) | BR112016025396A2 (enExample) |
| CA (1) | CA2948067A1 (enExample) |
| ES (1) | ES2701516T3 (enExample) |
| IL (1) | IL248744B (enExample) |
| MX (1) | MX2016014436A (enExample) |
| RU (1) | RU2016147727A (enExample) |
| SG (1) | SG11201609205WA (enExample) |
| WO (1) | WO2015169421A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3003600A1 (en) * | 2015-11-02 | 2017-05-11 | Merck Patent Gmbh | 1,4-dicarbonyl-piperidyl derivatives |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107226808B (zh) * | 2016-03-23 | 2021-01-01 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| PT3562822T (pt) | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| CN109251204A (zh) * | 2017-07-13 | 2019-01-22 | 中国药科大学 | 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途 |
| CN110698411B (zh) * | 2018-07-09 | 2023-05-09 | 四川大学 | 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途 |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CN109748923A (zh) * | 2019-01-31 | 2019-05-14 | 中国药科大学 | 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途 |
| CN117164418B (zh) * | 2023-08-18 | 2024-07-02 | 徐州医科大学 | 一种α-卤代酮、其高效合成方法及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| CA2841932A1 (en) | 2011-07-13 | 2013-01-17 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
| US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
| SG11201600743WA (en) | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
-
2015
- 2015-04-16 RU RU2016147727A patent/RU2016147727A/ru not_active Application Discontinuation
- 2015-04-16 WO PCT/EP2015/000793 patent/WO2015169421A1/en not_active Ceased
- 2015-04-16 EP EP15720259.9A patent/EP3140295B1/en not_active Not-in-force
- 2015-04-16 CA CA2948067A patent/CA2948067A1/en not_active Abandoned
- 2015-04-16 KR KR1020167033984A patent/KR102415436B1/ko not_active Expired - Fee Related
- 2015-04-16 CN CN201580023793.1A patent/CN106458988B/zh not_active Expired - Fee Related
- 2015-04-16 US US15/308,974 patent/US9809598B2/en not_active Expired - Fee Related
- 2015-04-16 MX MX2016014436A patent/MX2016014436A/es unknown
- 2015-04-16 AU AU2015258100A patent/AU2015258100B2/en not_active Ceased
- 2015-04-16 BR BR112016025396A patent/BR112016025396A2/pt not_active IP Right Cessation
- 2015-04-16 JP JP2016566920A patent/JP6673853B2/ja not_active Expired - Fee Related
- 2015-04-16 ES ES15720259T patent/ES2701516T3/es active Active
- 2015-04-16 SG SG11201609205WA patent/SG11201609205WA/en unknown
- 2015-05-07 AR ARP150101387A patent/AR100333A1/es unknown
-
2016
- 2016-11-03 IL IL248744A patent/IL248744B/en active IP Right Grant
-
2020
- 2020-01-29 JP JP2020012230A patent/JP6837585B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106458988B (zh) | 2019-12-03 |
| EP3140295A1 (en) | 2017-03-15 |
| CA2948067A1 (en) | 2015-11-12 |
| KR102415436B1 (ko) | 2022-06-30 |
| US9809598B2 (en) | 2017-11-07 |
| JP6837585B2 (ja) | 2021-03-03 |
| RU2016147727A3 (enExample) | 2018-10-25 |
| RU2016147727A (ru) | 2018-06-08 |
| AR100333A1 (es) | 2016-09-28 |
| JP2017517502A (ja) | 2017-06-29 |
| AU2015258100A1 (en) | 2016-12-22 |
| US20170073347A1 (en) | 2017-03-16 |
| EP3140295B1 (en) | 2018-09-12 |
| MX2016014436A (es) | 2017-01-23 |
| IL248744B (en) | 2020-11-30 |
| SG11201609205WA (en) | 2016-12-29 |
| WO2015169421A1 (en) | 2015-11-12 |
| JP6673853B2 (ja) | 2020-03-25 |
| ES2701516T3 (es) | 2019-02-22 |
| KR20160149277A (ko) | 2016-12-27 |
| IL248744A0 (en) | 2017-01-31 |
| BR112016025396A2 (pt) | 2017-08-15 |
| JP2020097596A (ja) | 2020-06-25 |
| CN106458988A (zh) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6837585B2 (ja) | ヘテロシクリル−ブタンアミド誘導体 | |
| EP3027598B1 (en) | Oxoquinazolinyl-butanamide derivatives | |
| EP3371166B1 (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| AU2014372896B2 (en) | Imidazopyrazinone derivatives | |
| CA2920537A1 (en) | Piperidine urea derivatives as inhibitors of tankyrase | |
| CA2916557A1 (en) | Phthalazine derivatives | |
| HK1222391B (en) | Oxoquinazolinyl-butanamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |